Evidence map›Paper›PMID 23150441›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2013

Determine the effect of p53 on chemosensitivity.

Emir Senturk, James J Manfredi

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emir SenturkMount Sinai School of Medicine, New York, NY, USA.
James J Manfredi
Icahn School of Medicine at Mount Sinai · US

Funding

Role of p53 in cell cycle checkpointsR01CA125741 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MANFREDI, JAMES J · 2009 to 2013
$1.7M
NCI NIH HHS R01 CA125741
6 · The paper itself

Abstract

The p53 tumor suppressor protein plays a central role in mediating the cellular response to a variety of stresses. Activation of p53 signaling will trigger cell cycle arrest or apoptosis in normal cells, depending on such factors as cell type and genetic context. The ability of a cell to circumvent either of these p53-directed outcomes leads to inappropriate proliferation, thereby contributing to the development of cancer. As such, tumors frequently escape the apoptotic pathway in response to cell stress. DNA-damaging agents, however, achieve significant tumor cytotoxicity in spite of this hallmark characteristic. Tumors treated with DNA-damaging drugs often undergo alternate forms of cell death, such as senescence or mitotic catastrophe, in addition to apoptosis that may ultimately lead to regression. Although not a predictor of chemotherapy response in patients per se, p53 status in tumor-derived cells is frequently a determinant of the death pathway promoted by these agents. The cytotoxic effects of DNA-damaging agents can be readily appreciated using such tools as cell cycle analysis, phopsho-H3(Ser10) immunoblotting, and annexin V detection.

Indexed as

Cellular SenescenceAnnexin A5ApoptosisCell CycleCell Line, TumorDNA DamageElectrophoresis, Polyacrylamide GelHistonesHumansImmunoblottingMitosisPropidiumTumor Suppressor Protein p53Annexin A5HistonesPropidiumTumor Suppressor Protein p53

Identifiers

PMID23150441
PMCPMC4704444
OpenAlexW2412613448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.